205 related articles for article (PubMed ID: 25328074)
1. Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study.
Giorda G; Gadducci A; Lucia E; Sorio R; Bounous VE; Sopracordevole F; Tinelli A; Baldassarre G; Campagnutta E
J Ovarian Res; 2014 Jul; 7():72. PubMed ID: 25328074
[TBL] [Abstract][Full Text] [Related]
2. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery.
Eoh KJ; Lee JY; Yoon JW; Nam EJ; Kim S; Kim SW; Kim YT
Oncotarget; 2017 Jun; 8(23):37807-37816. PubMed ID: 27906676
[TBL] [Abstract][Full Text] [Related]
3. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD
Cancer; 2017 May; 123(6):985-993. PubMed ID: 27864921
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
5. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
[TBL] [Abstract][Full Text] [Related]
6. Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer.
Derlatka P; Sienko J; Grabowska-Derlatka L; Palczewski P; Danska-Bidzinska A; Bidzinski M; Czajkowski K
World J Surg Oncol; 2016 Feb; 14():58. PubMed ID: 26923029
[TBL] [Abstract][Full Text] [Related]
7. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
[TBL] [Abstract][Full Text] [Related]
8. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
9. The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.
Bachmann C; Brucker SY; Kraemer B; Rothmund R; Staebler A; Fend F; Wallwiener D; Grischke EM
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1475-80. PubMed ID: 25739827
[TBL] [Abstract][Full Text] [Related]
10. Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer.
Gillette-Cloven N; Burger RA; Monk BJ; McMeekin DS; Vasilev S; DiSaia PJ; Kohler MF
J Am Coll Surg; 2001 Dec; 193(6):626-32. PubMed ID: 11768679
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
14. Hematogenous Splenic Metastases as an Independent Negative Prognosis Factor at the Moment of Primary Cytoreduction in Advanced Stage Epithelial Ovarian Cancer--A Single Center Experience.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Oct; 35(10):5649-54. PubMed ID: 26408738
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer.
Berretta R; Capozzi VA; Sozzi G; Volpi L; Ceni V; Melpignano M; Giordano G; Marchesi F; Monica M; Di Serio M; Riccò M; Ceccaroni M
Arch Gynecol Obstet; 2018 Apr; 297(4):997-1004. PubMed ID: 29380107
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Role of Optimal Cytoreduction in Advanced, Bowel Infiltrating Ovarian Cancer.
Bachmann R; Rothmund R; Krämer B; Brucker SY; Königsrainer A; Königsrainer I; Beckert S; Staebler A; NguyenHuu P; Grischke E; Wallwiener D; Bachmann C
J Invest Surg; 2015 Jun; 28(3):160-6. PubMed ID: 25565126
[TBL] [Abstract][Full Text] [Related]
17. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
18. Parenchymal liver metastasis in advanced ovarian cancer: Can bowel involvement influence the frequency and the related mortality rate?
Valenti G; Sopracordevole F; Chiofalo B; Forte S; Ciancio F; Fiore M; Giorda G
Eur J Obstet Gynecol Reprod Biol; 2023 Jan; 280():48-53. PubMed ID: 36399920
[TBL] [Abstract][Full Text] [Related]
19. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
Tseng JH; Cowan RA; Zhou Q; Iasonos A; Byrne M; Polcino T; Polen-De C; Gardner GJ; Sonoda Y; Zivanovic O; Abu-Rustum NR; Long Roche K; Chi DS
Gynecol Oncol; 2018 Oct; 151(1):24-31. PubMed ID: 30126704
[TBL] [Abstract][Full Text] [Related]
20. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer.
Plotti F; Montera R; Aloisi A; Scaletta G; Capriglione S; Luvero D; De Cicco Nardone C; Basile S; Benedetti Panici P; Angioli R
Eur J Surg Oncol; 2016 Mar; 42(3):383-90. PubMed ID: 26725211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]